Daily BriefsECM

Daily Brief ECM: Pre-IPO Hanx Biopharmaceuticals – The Risk of Pipeline Development Failure Is High and more

In today’s briefing:

  • Pre-IPO Hanx Biopharmaceuticals – The Risk of Pipeline Development Failure Is High
  • MIXUE Pre-IPO – Refiling Updates – Slower Growth but Better Margins
  • Hexaware Technologies IPO: Valuation Insights
  • Ajax Engineering IPO – Robust Growth Driven by a Comprehensive Dealer Network


Pre-IPO Hanx Biopharmaceuticals – The Risk of Pipeline Development Failure Is High

By Xinyao (Criss) Wang

  • CD47 has been considered “problematic” by the industry, so in order to prove its druggability, it usually requires very good clinical data, and cannot rely on “conjectures” such as BsAb. 
  • There’s no compelling evidence to prove that the toxicity issue of CD47 can be resolved. There’re concerns on the safety profile and efficacy of HX009/HX044, with high R&D failure risks.
  • After Series B+ of financing in June 2024, post-investment valuation of Hanx reached about RMB1.6 billion. Due to slower R&D progress. we think Hanx’s valuation should be lower than ImmuneOnco.  

MIXUE Pre-IPO – Refiling Updates – Slower Growth but Better Margins

By Sumeet Singh

  • Mixue Group is looking to raise about US$1bn in its upcoming Hong Kong IPO.
  • MIXUE Group (MIXUE) is a freshly-made drinks company providing affordable products to consumers, including freshly-made fruit drinks, tea, ice cream and coffee, typically priced at around one USD per item.
  • In our earlier notes, we have looked at the past performance, undertaken a peer comparison and spoken about valuations. In this note, we talk about updates from its recent filings.

Hexaware Technologies IPO: Valuation Insights

By Arun George


Ajax Engineering IPO – Robust Growth Driven by a Comprehensive Dealer Network

By Akshat Shah

  • Ajax Engineering Limited (0896529D IN) is looking to raise about US$145m in its upcoming India IPO.
  • Ajax Engineering Limited (AEL) is one of the leading concrete equipment manufacturers with a comprehensive range of concrete equipment, services and solutions across the concrete application value chain.
  • In this note, we take a quick look at the company’s past performance and the IPO valuations.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars